Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Transgene’s licenced oncolytic virus fails in Phase III

The interim futility analysis focussed on the question if the oncolytic virus Pexa-Vec (pexastimogene devacirepvec) plus sorafenib (Nexavar, Bayer)...

Partnership in pursuit of new antibiotics class

For forty years, no new antibiotic class targeting Enterobacteriaceae infections has come on the market. If all goes to plan, this overlong dry spell...

Breakthrough in liquid biopsy

Scientists from Germany and the US have created a laser-based platform that can quickly and noninvasively screen large quantities of blood in...

Billions for the circular economy

The flagship partnership aims to support the development and implementation of circular economy projects and programmes in the European Union. The...

PharmaMar moves ahead with NDA for Zepsyre

Although the Phase III trial for lurbinectedin won't have results for several months yet, PharmaMar is already submitting the drug for approval. The...

Wellington Partners launch €210m Life Sciences fund

The Munich-based European venture capital heavyweight's Life Science Fund V (€210m) is more than twice the size of its predecessor - the first...

Curetis lower respiratory tract panel ready for FDA clearance

With its 510(k) application to the US Food and Drug Administration (FDA), Curetis targets the US diagostics market for lower respiratory infections...